Viatris is divesting its Tyrvaya dry eye treatment to Harrow Inc. for up to $100 million, a strategic move to sharpen its focus on high-potential growth areas. Concurrently, Viatris reported strong Q2 earnings, beating consensus, and subsequently raised its full-year 2026 earnings and sales guidance, indicating improved financial performance and future confidence.
Viatris (VTRS) is undergoing a strategic divestiture of its Tyrvaya asset to Harrow Inc. (HROW) for up to $100 million, allowing Viatris to concentrate on core growth areas like complex generics and transdermal products, and the Greater China market. This move, coupled with better-than-expected Q2 earnings and an upward revision of its 2026 guidance, signals a positive shift in Viatris's operational efficiency and financial outlook. For Harrow, the acquisition of Tyrvaya expands its product portfolio in the dry eye disease market, offering potential for future revenue growth. While VTRS shares were down slightly on the news, the long-term implications of a more focused strategy and improved financial projections are generally positive for Viatris, and the acquisition is a growth opportunity for Harrow.